rs121918384 — APOB APOB Val1856fs

When the LDL Scaffold Breaks — APOB Frameshift and Fat-Soluble Vitamin Risk

Apolipoprotein B-100 (ApoB-100)¹¹ Apolipoprotein B-100 (ApoB-100)
The primary structural protein of LDL and VLDL particles; every LDL particle contains exactly one ApoB-100 molecule, which acts as a molecular scaffold and receptor-binding ligand is one of the largest proteins in the human body, spanning 4,536 amino acids. The rs121918384 variant deletes two nucleotides (CA) at coding position c.5566–5567 of the APOB gene, shifting the reading frame at amino acid 1856 and generating a premature stop codon. The result is a severely truncated ApoB fragment — roughly 40% of the full-length protein — that disrupts lipoprotein assembly and, in carriers of two deletion alleles, impairs the intestinal absorption of fat-soluble vitamins.

The Mechanism

Full-length ApoB-100 is the exclusive structural protein of LDL particles²² LDL particles
Low-density lipoprotein — the primary cholesterol-carrying particle in the bloodstream; each LDL contains exactly one ApoB-100 molecule that must be assembled intact for the particle to be secreted from hepatocytes. The Val1856fs frameshift truncates the protein at roughly amino acid 1,900, eliminating the C-terminal domain required for stable lipoprotein particle assembly. Truncated ApoB fragments shorter than approximately ApoB-37 are typically absent from plasma, suggesting they are degraded intracellularly before secretion.

In the intestine, a related isoform — ApoB-48 — is required to package dietary fat into chylomicrons for transport from the gut into the lymph. Because the Val1856fs truncation falls upstream of the ApoB-48 editing site (codon 2,153), homozygous carriers retain limited intestinal ApoB-48 function; however, total intestinal lipid transport is severely compromised, causing malabsorption of fat and fat-soluble vitamins (A, D, E, and K). Heterozygous carriers produce one normal full-length ApoB-100 allele, which is sufficient for adequate lipid transport in most settings.

The Evidence

Farese et al. (1992)³³ Farese et al. (1992) catalogued over 20 APOB frameshift and nonsense mutations causing familial hypobetalipoproteinemia (FHBL1). Heterozygotes show LDL cholesterol levels roughly one-quarter to one-third of unaffected family members, typically without symptoms. Homozygotes or compound heterozygotes develop "severe problems related to intestinal fat malabsorption" with LDL cholesterol often below 5–10 mg/dL.

Schonfeld's comprehensive review (1995)⁴⁴ Schonfeld's comprehensive review (1995) confirmed that heterozygous FHBL carriers have "lower-than-average risk for atherosclerotic cardiovascular disease" but should be monitored for hepatic steatosis and, in the small subset who develop symptoms, fat-soluble vitamin deficiency.

The 2021 GeneReviews entry by Burnett, Hooper, and Hegele⁵⁵ GeneReviews entry by Burnett, Hooper, and Hegele defines the full biallelic phenotype: fat-soluble vitamin E, A, D, and K deficiency; progressive neuropathy with loss of deep tendon reflexes, vibratory sense, and proprioception; ataxia; retinal pigment changes; and hepatic steatosis that can progress to fibrosis. Management of biallelic disease centers on high-dose fat-soluble vitamin supplementation (vitamin E 100–300 IU/kg/day, vitamin A 100–400 IU/kg/day, vitamin D 800–1,200 IU/day, and vitamin K 5–35 mg/week) to prevent irreversible neurological and retinal complications.

Zhang and Wang's 2023 case series⁶⁶ Zhang and Wang's 2023 case series reviewed 55 published cases of homozygous FHBL: 28 had lipid malabsorption, 25 had elevated transaminases, 21 had fatty liver, 14 had acanthocytosis, 10 had neurological symptoms, and 6 had ocular lesions — illustrating the multisystem reach of severely impaired lipoprotein assembly.

rs121918384 is exceptionally rare: the deletion allele appears in roughly 28 of 1.4 million alleles in gnomAD v4, almost exclusively in European-ancestry populations (allele frequency ~0.000024). Homozygosity is essentially absent in population data.

Practical Actions

Heterozygous carriers (DI genotype) usually remain asymptomatic and require no supplementation beyond baseline monitoring of lipids, liver enzymes, and — if any gastrointestinal symptoms arise — fat-soluble vitamin levels. The low LDL profile typically observed in heterozygotes is actually cardioprotective; it is the hepatic steatosis risk and the rare onset of symptoms that warrant periodic assessment.

Biallelic carriers (DD genotype, the only homozygotes in real clinical populations given the variant's rarity) require specialist-guided management with high-dose fat-soluble vitamins initiated early, before neurological or retinal complications become irreversible.

Interactions

APOB rs121918384 heterozygosity creates a low-LDL baseline that can interact unexpectedly with statins or PCSK9 inhibitors (rs11591147): combining this variant with drugs that further suppress ApoB production may produce unusually low LDL levels warranting closer lipid monitoring. Within the APOB gene, other truncating variants (rs5742904 and rs1367117) produce similar hypobetalipoproteinemic phenotypes and would compound effects in carriers of two different APOB loss-of-function alleles.